$599

Lipocine Ph2 Obesity Results; 89bio Enters Manufacturing Partnership

Two cardiometabolic-related news items have been observed: Lipocine announced results from a Ph2 trial evaluating LPCN 2401, an oral combination of α-tocopherol and anabolic androgen receptor agonist, in obese/overweight participants (view press release); and 89bio entered a collaboration with BiBo Biopharma Engineering to build a production facility in China to manufacture a commercial supply of pegozafermin (view 8-K SEC filing). Below, FENIX provides highlights and insights into the respective items, including thoughts on the risk 89bio is taking since pegozafermin has not yet completed clinical development.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.